気管支拡張薬の市場規模、シェア、動向分析レポート：疾患別（喘息、COPD）、投与経路別（吸入、経口）、薬物クラス別（β-アドレナリン、抗コリン）、地域別、およびセグメント予測、2023年～2030年

気管支拡張薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、気管支拡張薬の世界市場は2030年までに287億5000万米ドルに達し、2023年から2030年まで年平均成長率（CAGR）3.29%で拡大すると予測されているとのことです。気管支拡張薬市場の成長の背景には、老年人口の増加や呼吸器系疾患を持つ人口の増加が挙げられます。さらに、慢性閉塞性肺疾患（COPD）や喘息などの呼吸器疾患は、高齢者層でより一般的になっています。

気管支拡張薬の需要は、呼吸器系疾患の増加により、著しく伸びています。喫煙者の急増により、喘息やCOPDなどの肺疾患のリスクが高い人口が増加しています。例えば、2021年のWHOの発表によると、世界には13億人以上の喫煙者がおり、その80％はLMICに位置していると言われています。このような人々は、肺機能の悪化が加速し、死亡率も上昇します。米国肺協会によると、喘息患者の17％が喫煙者であり、非喘息患者の13.7％と比較して、喫煙者の割合が高いことが分かっています。このため、気管支拡張薬を持続的に使用する必要があり、気管支拡張薬の需要が加速しています。

さらに、国民の意識を高めるために、公的機関や民間企業による取り組みも増えています。GOLD（Global Initiative for Chronic Obstructive Lung Disease）などの国際機関は、世界中の公衆衛生当局や医療専門家と協力し、世界中でCOPDに対する認識を高め、治療と予防を改善するために活動しています。さらに、アストラゼネカ、シプラ、テバなどの企業は、「Get Real」、「#Laugh4Lungs」、「Inhalers are Right for Asthma」、「Inhaler is boon for Asthma」などのソーシャルメディアを通じて、認知度を高めるための活動を展開しています。これらのキャンペーンは、患者の意識を高め、より多くの気管支拡張薬の使用を促し、予防措置を講じることで患者の生活を守ることを可能にします。さらに、呼吸器疾患患者のための効果的な治療法を開発するために、地域の市場関係者が研究開発に取り組んでいることから、市場の拡大が見込まれています。

企業は、アンメットメディカルニーズに対応するため、新規治療法を開発するために共同研究を行っています。これにより、企業はそのリソースを製品開発やサプライチェーンの改善に役立てることができます。さらに、多くのプレイヤーが、製品ポートフォリオを拡大するために、製品の上市に注力しています。例えば、2021年9月、アストラゼネカは、喘息患者の治療のために吸入コルチコステロイド（ICS）ブデソニドとβ2アゴニスト（SABA）アルブテロールの組み合わせ製剤に取り組み始め、これが承認されれば、米国で初の喘息のICS/SABAコンボ救援吸入器として期待されるでしょう。

気管支拡張薬市場レポートハイライト

2022年の市場セグメンテーションでは、需要の増加に伴いFDAによるジェネリック医薬品の承認が増加し、βアドレナリン系気管支拡張薬セグメントが圧倒的なシェアを占める

経口剤は、臨床医や患者から2番目に好まれる投与方法であるため、予測期間中に最も速い速度で成長すると予測される

2022年の市場セグメンテーションでは、世界の疾病の増加により、喘息領域が圧倒的なシェアを占める

2022年の市場は北米が支配的であり、これは同地域における主要な市場プレイヤーの存在、高度に発達したヘルスケアインフラ、より良い価格設定に起因しています。

目次

第1章 調査手法と範囲

• 市場セグメンテーション
• 調査手法
• 情報調達
  • 購入したデータベース
  • 二次情報
  • 1次調査
  • 1次調査の詳細
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析
    • アプローチ1：コモディティフローアプローチ
    • アプローチ2：ボトムアップアプローチを使用した国ごとの市場推定
• 世界市場：CAGR計算
• 調査の仮定
• 二次情報のリスト
• 一次情報のリスト
• 目的
• 略語一覧

第2章 気管支拡張薬市場-エグゼクティブサマリー

• 市場のスナップショット
• セグメントのスナップショット
• 競合情勢のスナップショット

第3章 気管支拡張薬市場の変数、動向、範囲

• 気管支拡張薬市場系統の見通し
  • 親市場の見通し
    • 世界の喘息およびCopd市場
  • アンシラリー市場の見通し
    • ブランドジェネリック市場
    • 院内感染治療薬市場
• 浸透と成長の見通しのマッピング
• 市場促進要因分析
  • 高齢者人口の増加
  • 肺疾患の有病率の増加
  • 肺疾患の治療に関する意識の高まり
  • 喫煙者数の増加
  • プレイヤー別研究開発の取り組みのエスカレーション
  • 世界の汚染レベルの上昇
• 市場抑制要因分析
  • 長い承認時間と厳しい規制
  • 気管支拡張薬の悪影響
• SWOT分析、要因別（政治と法律、経済、技術）
• ポーターのファイブフォース分析
• 規制の枠組み

第4章 気管支拡張薬市場- セグメント分析、薬剤クラス別、2018年-2030年（100万米ドル）

• 定義と範囲
• 気管支拡張薬市場：薬物クラスの変動分析
  • ベータアドレナリン気管支拡張薬
  • 抗コリン性気管支拡張薬
  • キサンチン誘導体

第5章 気管支拡張薬市場-セグメント分析、投与経路別、2018年から2030年（100万米ドル）

• 気管支拡張薬市場：投与経路の変動分析
  • オーラル
  • 鼻（吸入可能）
  • 注射可能

第6章 気管支拡張薬市場-セグメント分析、最終用途別、2018年から2030年（100万米ドル）

• 定義と範囲
• 気管支拡張薬市場：疾患変動分析
  • 喘息
  • 慢性閉塞性肺疾患（Copd）
  • その他

第7章 気管支拡張薬市場-地域ビジネス分析

• 定義と範囲
• 地域市場シェア分析、2022年および2030年
• 地域市場ダッシュボード
• 地域市場のスナップショット
• SWOT分析、要因別（政治と法律、経済と技術）
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • MEA
• 市場規模、予測、トレンド分析、2022年から2030年
• 北米
  • 米国
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • カナダ
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
• 欧州
  • 英国
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • ドイツ
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • スペイン
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • フランス
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • イタリア
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • デンマーク
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • スウェーデン
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • ノルウェー
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
• アジア太平洋地域
  • 日本
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • 中国
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • インド
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • 韓国
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • タイ
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • オーストラリア
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
• ラテンアメリカ
  • ブラジル
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • メキシコ
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • アルゼンチン
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
• MEA
  • 南アフリカ
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • サウジアラビア
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • アラブ首長国連邦
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ
  • クウェート
    • 主要な国のダイナミクス
    • 規制の枠組み
    • 競合シナリオ
    • 最近の開発
    • 投資シナリオ

第8章 気管支拡張薬市場-競合分析

• 企業/競合の分類（主要なイノベーター、マーケットリーダー、新興企業）
• 戦略的枠組み
• 市場参加の分類
• 主要な市場参入企業別最近の動向と影響分析
• 会社のポジション分析
• 代理店一覧
  • 主要顧客
  • 公開会社
  • 非公開会社

第9章 気管支拡張薬市場-企業プロファイル

• 企業プロファイル
  • Gsk Plc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Astrazeneca
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Teva Pharmaceutical Industries Ltd.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Cipla Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Mylan NV
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Merck &Co., Inc.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Novartis Ag
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Boehringer Ingelheim International Gmbh.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Sun Pharmaceutical Industries Ltd.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • Glenmark Pharmaceuticals Limited
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Regulatory Framework
• Table 4 Global Bronchodilators Market, By Region, 2018 - 2030 (USD Million)
• Table 5 Global Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 6 Global Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 7 Global Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 8 North America Bronchodilators Market, By Country, 2018 - 2030, (USD Million)
• Table 9 North America Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 10 North America Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 11 North America Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 12 U.S. Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 13 U.S. Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 14 U.S. Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 15 Canada Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 16 Canada Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 17 Canada Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 18 Europe Bronchodilators Market, By Country, 2018 - 2030, (USD Million)
• Table 19 Europe Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 20 Europe Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 21 Europe Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 22 U.K. Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 23 U.K. Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 24 U.K. Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 25 Germany Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 26 Germany Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 27 Germany Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 28 France Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 29 France Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 30 France Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 31 Spain Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 32 Spain Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 33 Spain Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 34 Italy Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 35 Italy Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 36 Italy Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 37 Denmark Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 38 Denmark Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 39 Denmark Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 40 Sweden Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 41 Sweden Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 42 Sweden Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 43 Norway Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 44 Norway Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 45 Norway Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific Bronchodilators Market, By Country, 2018 - 2030, (USD Million)
• Table 47 Asia Pacific Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 50 Japan Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 51 Japan Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 52 Japan Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 53 China Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 54 China Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 55 China Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 56 Australia Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 57 Australia Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 58 Australia Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 59 Thailand Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 60 Thailand Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 61 Thailand Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 62 India Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 63 India Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 64 India Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 65 South Korea Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 66 South Korea Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 67 South Korea Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 68 Latin America Bronchodilators Market, By Country, 2018 - 2030, (USD Million)
• Table 69 Latin America Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 70 Latin America Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 71 Latin America Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 72 Mexico Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 73 Mexico Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 74 Mexico Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 75 Brazil Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 76 Brazil Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 77 Brazil Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 78 Argentina Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 79 Argentina Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 80 Argentina Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 81 MEA Bronchodilators Market, By Country, 2018 - 2030, (USD Million)
• Table 82 MEA Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 83 MEA Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 84 MEA Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 85 South Africa Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 86 South Africa Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 87 South Africa Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 89 Saudi Arabia Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 90 Saudi Arabia Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 91 UAE Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 92 UAE Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 93 UAE Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
• Table 94 Kuwait Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 95 Kuwait Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 96 Kuwait Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Bronchodilators market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Bronchodilators market snapshot
• Fig. 10 Penetration and growth prospect mapping for application, 2022 (USD million)
• Fig. 11 Market Dynamics
• Fig. 12 Bronchodilators market driver impact
• Fig. 13 Bronchodilators market restraint impact
• Fig. 14 Porter's five forces analysis
• Fig. 15 Bronchodilators market: Drug type outlook and key takeaways
• Fig. 16 Beta-adrenergic bronchodilators market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 17 Anticholinergic bronchodilators market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Xanthine derivative market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Bronchodilators market: Cancer type outlook and key takeaways
• Fig. 20 Bronchodilators market: Route of administration movement analysis
• Fig. 21 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Nasal (Inhalation) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Bronchodilators market: Disease outlook and key takeaways
• Fig. 25 Bronchodilators market: Disease movement analysis
• Fig. 26 Asthma market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Chronic obstructive pulmonary disease (COPD) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Bronchodilators Market: Regional outlook and key takeaways
• Fig. 30 Bronchodilators Market: Regional movement analysis
• Fig. 31 North America
• Fig. 32 North America market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 U.S.
• Fig. 34 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Canada
• Fig. 36 Canada market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Europe
• Fig. 38 Europe market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 U.K.
• Fig. 40 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 41 Germany
• Fig. 42 Germany market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 France
• Fig. 44 France market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 45 Spain
• Fig. 46 Spain market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 47 Italy
• Fig. 48 Italy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 49 Denmark
• Fig. 50 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 51 Sweden
• Fig. 52 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 53 Norway
• Fig. 54 Norway market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 55 Asia Pacific
• Fig. 56 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 57 Japan
• Fig. 58 Japan market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 59 China
• Fig. 60 China market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 61 India
• Fig. 62 India market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 63 Thailand
• Fig. 64 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 65 Australia
• Fig. 66 Australia market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 67 South Korea
• Fig. 68 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 69 Latin America
• Fig. 70 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 71 Brazil
• Fig. 72 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 73 Mexico
• Fig. 74 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 75 Argentina
• Fig. 76 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 77 MEA
• Fig. 78 MEA market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 79 South Africa
• Fig. 80 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 81 Saudi Arabia
• Fig. 82 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 83 UAE
• Fig. 84 UAE market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 85 Kuwait
• Fig. 86 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 87 Ansoff Matrix
• Fig. 88 Strategy mapping
• Fig. 89 Company market share analysis, 2022
• Fig. 90 Heat Map Analysis
• Fig. 91 Market differentiators
• Fig. 92 Heat Map Analysis

Bronchodilators Market Growth & Trends:

The global bronchodilators market is expected to reach USD 28.75 billion by 2030 and is expected to expand at a compound annual growth rate (CAGR) of 3.29% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the bronchodilators market is attributed to the increasing geriatric population and rising population with respiratory disorders. Moreover, respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma are more common among the elderly population.

The demand for bronchodilators is growing significantly, owing to the increasing incidence of respiratory disorders. The surging number of smokers is increasing the population with a heightened risk of lung conditions such as asthma and COPD. For instance, as per WHO in 2021, there are over 1.3 billion smokers globally with 80% of them situated in LMIC's. This population has an accelerated rate of deterioration in lung function along with intensified mortality rate. As per American Lung Association, 17% of the population with asthma are smokers which is 13.7% in the non-asthmatic population. This creates a need for persistent use of bronchodilators in patients, thereby, accelerating the demand for bronchodilators.

Moreover, there are increasing efforts from public and private organizations to increase awareness among the population. International organizations such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) are working with public health officials and healthcare professionals worldwide to increase awareness and improve the treatment and prevention of COPD around the world. Moreover, companies such as AstraZeneca, Cipla, Teva, and several others have been trying to spread awareness through social media platforms such as 'Get Real', #Laugh4Lungs', 'Inhalers are Right for Asthma', 'Inhaler is boon for Asthma', and many more. These campaigns help raise awareness and encourage patients towards using more bronchodilators and enable them to secure their lives by taking preventive measures. Furthermore, the market is expected to grow due to regional market players ongoing R&D efforts to develop an effective treatment for patients with respiratory disorders.

Companies are collaborating to develop novel treatments to address unmet medical needs. This enables businesses to use their resources to help with product development and supply chain improvements. Moreover, a number of players are also focusing on product launches in order to expand their product portfolio. For instance, in September 2021, AstraZeneca started working on a combination formulation of inhaled corticosteroid (ICS) budesonide and beta2-agonist (SABA) albuterol for the treatment of patients with Asthma, which if approved is expected to be the first ICS/SABA combo rescue inhaler for asthma in the U.S.

Bronchodilators Market Report Highlights:

• Beta adrenergic bronchodilators segment held a dominant share in the market in 2022, owing to the increasing number of generic approvals by the FDA to meet the rising demands

• Oral segment is projected to grow at the fastest rate over the forecast period attributable to it being the second most preferred mode of administration amongst clinicians and patients

• Asthma segment held a dominant share of the market in 2022 owing to the increasing prevalence of target diseases worldwide

• North America dominated the market in 2022, which is attributed to the presence of key market players in the region, highly developed healthcare infrastructure, better affordability

Table of Contents

Chapter 1 Methodology And Scope

• 1.1 Market Segmentation
  • 1.1.1 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 Secondary Sources
  • 1.3.3 Primary Research
  • 1.3.4 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom-Up Approach
• 1.7 Global Market: Cagr Calculation
• 1.8 Research Assumptions
• 1.9 List Of Secondary Sources
• 1.10 List Of Primary Sources
• 1.11 Objectives
  • 1.11.1 Objective 1
  • 1.11.2 Objective 2
• 1.12 List Of Abbreviations

Chapter 2 Bronchodilators Market - Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot
• 2.3 Competitive Landscape Snapshot

Chapter 3 Bronchodilators Market Variables, Trends & Scope

• 3.1 Bronchodilators Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
    • 3.1.1.1 Global Asthma And Copd Market
  • 3.1.2 Ancillary Market Outlook
    • 3.1.2.1 Branded Generics Market
    • 3.1.2.2 Hospital-Acquired Infection Therapeutics Market
• 3.2 Penetration And Growth Prospect Mapping
• 3.3 Market Driver Analysis
  • 3.3.1 Growing Geriatric Population
  • 3.3.2 Increasing Prevalence Of Lung Diseases
  • 3.3.3 Rising Awareness About Treatment Of Lung Diseases
  • 3.3.4. Increase In Number Of Smokers
  • 3.3.5. Escalating R&D Efforts By Players
  • 3.3.6. Heightened Pollution Levels Globally
• 3.4 Market Restraint Analysis
  • 3.4.1 Long Approvals Times And Stringent Regulations
  • 3.4.2 Adverse Effects Of Bronchodilators
• 3.5 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
• 3.6 Porter's Five Forces Analysis
• 3.7 Regulatory Framework

Chapter 4 Bronchodilators Market - Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)

• 4.1 Definition And Scope
• 4.2 Bronchodilators Market: Drug Class Movement Analysis
  • 4.2.1 Beta-Adrenergic Bronchodilators
    • 4.2.1.1 Beta-Adrenergic Bronchodilators Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.2.2 Anticholinergic Bronchodilators
    • 4.2.2.1 Anticholinergic Bronchodilators Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.2.3 Xanthine Derivatives
    • 4.2.3.1 Xanthine Derivatives Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5 Bronchodilators Market - Segment Analysis, By Route Of Administration, 2018 - 2030 (USD Million)

• 5.1 Bronchodilators Market: Route Of Administration Movement Analysis
  • 5.1.1 Oral
    • 5.1.1.1 Oral Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.1.2 Nasal (Inhalable)
    • 5.1.2.1 Nasal (Inhalable) Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.1.3 Injectable
    • 5.1.3.1 Injectable Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Bronchodilators Market - Segment Analysis, By End-Use, 2018 - 2030 (USD Million)

• 6.1 Definition And Scope
• 6.2 Bronchodilators Market: Disease Movement Analysis
  • 6.2.1 Asthma
    • 6.2.1.1 Asthma Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.2.2 Chronic Obstructive Pulmonary Disease (Copd)
    • 6.2.2.1 Chronic Obstructive Pulmonary Disease (Copd) Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.2.3 Others
    • 6.2.3.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Bronchodilators Market - Regional Business Analysis

• 7.1 Definition & Scope
• 7.2 Regional Market Share Analysis, 2022 & 2030
• 7.3 Regional Market Dashboard
• 7.4 Regional Market Snapshot
• 7.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
  • 7.5.1 North America
  • 7.5.2 Europe
  • 7.5.3 Asia Pacific
  • 7.5.4 Latin America
  • 7.5.5 MEA
• 7.6 Market Size, & Forecasts, Trend Analysis, 2022 To 2030
• 7.7 North America
  • 7.7.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.7.2 U.S.
    • 7.7.2.1 U.S. Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.7.2.2 Key Country Dynamics
    • 7.7.2.3 Regulatory Framework
    • 7.7.2.4 Competitive Scenario
    • 7.7.2.5 Recent Developments
    • 7.7.2.6 Investments Scenario
  • 7.7.3 Canada
    • 7.7.3.1 Canada Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.7.3.2 Key Country Dynamics
    • 7.7.3.3 Regulatory Framework
    • 7.7.3.4 Competitive Scenario
    • 7.7.3.5 Recent Developments
    • 7.7.3.6 Investments Scenario
• 7.8 Europe
  • 7.8.1 Europe Bronchodilators Market, 2018 - 2030 (USD Million)
  • 7.8.2 U.K.
    • 7.8.2.1 U.K. Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.8.2.2 Key Country Dynamics
    • 7.8.2.3 Regulatory Framework
    • 7.8.2.4 Competitive Scenario
    • 7.8.2.5 Recent Developments
    • 7.8.2.6 Investments Scenario
  • 7.8.3 Germany
    • 7.8.3.1 Germany Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.8.3.2 Key Country Dynamics
    • 7.8.3.3 Regulatory Framework
    • 7.8.3.4 Competitive Scenario
    • 7.8.3.5 Recent Developments
    • 7.8.3.6 Investments Scenario
  • 7.8.4 Spain
    • 7.8.4.1 Spain Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.8.4.2 Key Country Dynamics
    • 7.8.4.3 Regulatory Framework
    • 7.8.4.4 Competitive Scenario
    • 7.8.4.5 Recent Developments
    • 7.8.4.6 Investments Scenario
  • 7.8.5 France
    • 7.8.5.1 France Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.8.5.2 Key Country Dynamics
    • 7.8.5.3 Regulatory Framework
    • 7.8.5.4 Competitive Scenario
    • 7.8.5.5 Recent Developments
    • 7.8.5.6 Investments Scenario
  • 7.8.6 Italy
    • 7.8.6.1 Italy Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.8.6.2 Key Country Dynamics
    • 7.8.6.3 Regulatory Framework
    • 7.8.6.4 Competitive Scenario
    • 7.8.6.5 Recent Developments
    • 7.8.6.6 Investments Scenario
  • 7.8.7 Denmark
    • 7.8.7.1 Denmark Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.8.7.2 Key Country Dynamics
    • 7.8.7.3 Regulatory Framework
    • 7.8.7.4 Competitive Scenario
    • 7.8.7.5 Recent Developments
    • 7.8.7.6 Investments Scenario
  • 7.8.8 Sweden
    • 7.8.8.1 Sweden Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.8.8.2 Key Country Dynamics
    • 7.8.8.3 Regulatory Framework
    • 7.8.8.4 Competitive Scenario
    • 7.8.8.5 Recent Developments
    • 7.8.8.6 Investments Scenario
  • 7.8.9 Norway
    • 7.8.9.1 Norway Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.8.9.2 Key Country Dynamics
    • 7.8.9.3 Regulatory Framework
    • 7.8.9.4 Competitive Scenario
    • 7.8.9.5 Recent Developments
    • 7.8.9.6 Investments Scenario
• 7.9 Asia Pacific
  • 7.9.1 Asia-Pacific Bronchodilators Market, 2018 - 2030 (USD Million)
  • 7.9.2 Japan
    • 7.9.2.1 Japan Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.9.2.2 Key Country Dynamics
    • 7.9.2.3 Regulatory Framework
    • 7.9.2.4 Competitive Scenario
    • 7.9.2.5 Recent Developments
    • 7.9.2.6 Investments Scenario
  • 7.9.3 China
    • 7.9.3.1 China Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.9.3.2 Key Country Dynamics
    • 7.9.3.3 Regulatory Framework
    • 7.9.3.4 Competitive Scenario
    • 7.9.3.5 Recent Developments
    • 7.9.3.6 Investments Scenario
  • 7.9.4 India
    • 7.9.4.1 India Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.9.4.2 Key Country Dynamics
    • 7.9.4.3 Regulatory Framework
    • 7.9.4.4 Competitive Scenario
    • 7.9.4.5 Recent Developments
    • 7.9.4.6 Investments Scenario
  • 7.9.5 South Korea
    • 7.9.5.1 South Korea Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.9.5.2 Key Country Dynamics
    • 7.9.5.3 Regulatory Framework
    • 7.9.5.4 Competitive Scenario
    • 7.9.5.5 Recent Developments
    • 7.9.5.6 Investments Scenario
  • 7.9.6 Thailand
    • 7.9.6.1 Thailand Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.9.6.2 Key Country Dynamics
    • 7.9.6.3 Regulatory Framework
    • 7.9.6.4 Competitive Scenario
    • 7.9.6.5 Recent Developments
    • 7.9.6.6 Investments Scenario
  • 7.9.7 Australia
    • 7.9.7.1 Australia Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.9.7.2 Key Country Dynamics
    • 7.9.7.3 Regulatory Framework
    • 7.9.7.4 Competitive Scenario
    • 7.9.7.5 Recent Developments
    • 7.9.7.6 Investments Scenario
• 7.10 Latin America
  • 7.10.1 Latin America Bronchodilators Market, 2018 - 2030 (USD Million)
  • 7.10.2 Brazil
    • 7.10.2.1 Brazil Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.10.2.2 Key Country Dynamics
    • 7.10.2.3 Regulatory Framework
    • 7.10.2.4 Competitive Scenario
    • 7.10.2.5 Recent Developments
    • 7.10.2.6 Investments Scenario
  • 7.10.3 Mexico
    • 7.10.3.1 Mexico Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.10.3.2 Key Country Dynamics
    • 7.10.3.3 Regulatory Framework
    • 7.10.3.4 Competitive Scenario
    • 7.10.3.5 Recent Developments
    • 7.10.3.6 Investments Scenario
  • 7.10.4 Argentina
    • 7.10.4.1 Argentina Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.10.4.2 Key Country Dynamics
    • 7.10.4.3 Regulatory Framework
    • 7.10.4.4 Competitive Scenario
    • 7.10.4.5 Recent Developments
    • 7.10.4.6 Investments Scenario
• 7.11 MEA
  • 7.11.1 MEA Bronchodilators Market, 2018 - 2030 (USD Million)
  • 7.11.2 South Africa
    • 7.11.2.1 South Africa Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.11.2.2 Key Country Dynamics
    • 7.11.2.3 Regulatory Framework
    • 7.11.2.4 Competitive Scenario
    • 7.11.2.5 Recent Developments
    • 7.11.2.6 Investments Scenario
  • 7.11.3 Saudi Arabia
    • 7.11.3.1 Saudi Arabia Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.11.3.2 Key Country Dynamics
    • 7.11.3.3 Regulatory Framework
    • 7.11.3.4 Competitive Scenario
    • 7.11.3.5 Recent Developments
    • 7.11.3.6 Investments Scenario
  • 7.11.4 UAE
    • 7.11.4.1 UAE Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.11.4.2 Key Country Dynamics
    • 7.11.4.3 Regulatory Framework
    • 7.11.4.4 Competitive Scenario
    • 7.11.4.5 Recent Developments
    • 7.11.4.6 Investments Scenario
  • 7.11.5 Kuwait
    • 7.11.5.1 Kuwait Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.11.5.2 Key Country Dynamics
    • 7.11.5.3 Regulatory Framework
    • 7.11.5.4 Competitive Scenario
    • 7.11.5.5 Recent Developments
    • 7.11.5.6 Investments Scenario

Chapter 8 Bronchodilators Market - Competitive Analysis

• 8.1 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
• 8.2 Strategy Framework
• 8.3 Market Participation Categorization
• 8.4 Recent Developments & Impact Analysis, By Key Market Participants
• 8.5 Company Position Analysis
• 8.6 List Of Distributors
  • 8.6.1 Key Customers
  • 8.6.2 Public Companies
  • 8.6.3 Private Companies

Chapter 9 Bronchodilators Market - Company Profiles

• 9.1 Company Profiles
  • 9.1.1 Gsk Plc.
    • 9.1.1.1 Company Overview
    • 9.1.1.2 Financial Performance
    • 9.1.1.3 Product Benchmarking
    • 9.1.1.4 Strategic Initiatives
  • 9.1.2 Astrazeneca
    • 9.1.2.1 Company Overview
    • 9.1.2.2 Financial Performance
    • 9.1.2.3 Product Benchmarking
    • 9.1.2.4 Strategic Initiatives
  • 9.1.3 Teva Pharmaceutical Industries Ltd.
    • 9.1.3.1 Company Overview
    • 9.1.3.2 Financial Performance
    • 9.1.3.3 Product Benchmarking
    • 9.1.3.4 Strategic Initiatives
  • 9.1.4 Cipla Inc.
    • 9.1.4.1 Company Overview
    • 9.1.4.2 Financial Performance
    • 9.1.4.3 Product Benchmarking
    • 9.1.4.4 Strategic Initiatives
  • 9.1.5 Mylan N.V.
    • 9.1.5.1 Company Overview
    • 9.1.5.2 Financial Performance
    • 9.1.5.3 Product Benchmarking
    • 9.1.5.4 Strategic Initiatives
  • 9.1.6 Merck & Co., Inc.
    • 9.1.6.1 Company Overview
    • 9.1.6.2 Financial Performance
    • 9.1.6.3 Product Benchmarking
    • 9.1.6.4 Strategic Initiatives
  • 9.1.7 Novartis Ag
    • 9.1.7.1 Company Overview
    • 9.1.7.2 Financial Performance
    • 9.1.7.3 Product Benchmarking
    • 9.1.7.4 Strategic Initiatives
  • 9.1.8 Boehringer Ingelheim International Gmbh.
    • 9.1.8.1 Company Overview
    • 9.1.8.2 Financial Performance
    • 9.1.8.3 Product Benchmarking
    • 9.1.8.4 Strategic Initiatives
  • 9.1.9 Sun Pharmaceutical Industries Ltd.
    • 9.1.9.1 Company Overview
    • 9.1.9.2 Financial Performance
    • 9.1.9.3 Product Benchmarking
    • 9.1.9.4 Strategic Initiatives
  • 9.1.10 Glenmark Pharmaceuticals Limited
    • 9.1.10.1 Company Overview
    • 9.1.10.2 Financial Performance
    • 9.1.10.3 Product Benchmarking
    • 9.1.10.4 Strategic Initiatives